Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) CFO Robert J. Jr. Marshall sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $71.58, for a total value of $357,900.00. Following the completion of the sale, the chief financial officer now owns 128,298 shares in the company, valued at approximately $9,183,570.84. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Lantheus Price Performance
Lantheus stock opened at $77.84 on Friday. The stock has a market capitalization of $5.26 billion, a price-to-earnings ratio of 228.94 and a beta of 0.64. Lantheus Holdings, Inc. has a 52-week low of $47.46 and a 52-week high of $87.47. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.59 and a current ratio of 2.74. The stock’s 50 day moving average price is $62.11 and its two-hundred day moving average price is $63.82.
Lantheus (NASDAQ:LNTH – Get Rating) last issued its earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.41. Lantheus had a net margin of 3.00% and a return on equity of 51.60%. The business had revenue of $263.17 million for the quarter, compared to analyst estimates of $244.61 million. On average, equities analysts predict that Lantheus Holdings, Inc. will post 4.46 earnings per share for the current year.
Institutional Trading of Lantheus
Analyst Upgrades and Downgrades
LNTH has been the topic of several analyst reports. JMP Securities started coverage on Lantheus in a report on Wednesday, March 8th. They issued an “outperform” rating and a $120.00 target price on the stock. SVB Leerink initiated coverage on shares of Lantheus in a research note on Wednesday, November 30th. They issued an “outperform” rating on the stock. Mizuho increased their price objective on shares of Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, February 24th. Finally, StockNews.com started coverage on shares of Lantheus in a report on Thursday. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.
Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.